Celcuity, Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company focused on precision oncology for women’s cancers. The company applies its proprietary signal transduction profiling platform to identify critical aberrations in tumor cell pathways, enabling the development of targeted therapeutic candidates alongside companion diagnostics. By matching patients to therapies most likely to yield a response, Celcuity aims to improve clinical outcomes and reduce unnecessary exposure to ineffective treatments.
At the core of Celcuity’s pipeline is OvaRex, a first-in-class immunotherapy designed to engage specific cell surface receptors expressed in ovarian cancer. OvaRex is being evaluated in early-stage clinical trials, supported by a companion diagnostic assay that stratifies patients based on tumor biomarker signatures. This dual approach underscores the company’s strategy of integrating therapeutic and diagnostic innovation to advance precision medicine in gynecologic oncology.
Founded in 2013 and headquartered in La Jolla, California, Celcuity completed its initial public offering in 2018 and has since expanded its development activities across the United States and Europe. The company collaborates with leading academic and clinical research centers to conduct translational studies and early-phase trials. Celcuity’s research and manufacturing operations are supported by strategic partnerships that bolster its capabilities in assay development, biomanufacturing, and regulatory support.
Celcuity is led by a management team with extensive experience in oncology drug development, diagnostic innovation and commercialization. The executive leadership includes a chief executive officer with more than two decades in life-science strategy and operations, alongside a senior scientific team that has originated multiple investigational therapies from concept through clinical proof-of-concept. This seasoned leadership cadre positions Celcuity to advance its precision oncology platform toward value-driving milestones and future regulatory filings.
AI Generated. May Contain Errors.
